Decentralized Trial Technology Insights

  1. How One Pharma Company Is Embracing Digital Technologies 12/21/2022

    The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

  2. 4 Essential Drivers In Clinical Development For Emerging Biotechs 12/21/2022

    Enrollment, enrollment, enrollment has been the sponsor’s classic mantra for achieving success in a clinical trial. Rather, we should replace this notion with four equally essential building blocks: 1) the selection of the right CRO, 2) the identification of study sites, 3) the engagement of sites, and 4) the enrollment of patients.

  3. The Future Of TransCelerate: Clinical Trial Modernization 12/19/2022

    In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

  4. Boehringer Ingelheim Implements One Medicine Technology Platform 12/8/2022

    For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

  5. What Astellas Has Learned About Decentralized Trials 11/28/2022

    When the COVID pandemic hit in the spring of 2020, many companies were unprepared for the changes that were about to impact their studies. Astellas is one company that was better prepared than most. The company had initiated a formalized, internal project on decentralized clinical trial (DCT) technologies and their use in clinical trials about nine months prior to the pandemic.

  6. Key Learnings To Optimize Clinical Trials During COVID-19 11/4/2022

    Designing and conducting trials during the COVID-19 global pandemic forced clinical teams to be creative, to explore the use of technology, and to design a trial that meets the participants where they are — without compromising outcomes. 

  7. What Your Sites Love And Hate About DCTs 10/25/2022

    For years, sponsor companies have had access to new and emerging technologies that would ease the participation burden of patients in clinical trials. While these emerging technologies helped sponsor companies keep their trials on track, they have also been a burden for the clinical sites having to deal with the changes required to keep up with them. Do you know where your sites stand on the adoption of hybrid trials and DCTs?

  8. Will DCTs Become The Norm? 10/5/2022

    Decentralized clinical trials (DCTs) have been an option for more than a decade, though the pandemic has been the catalyst for change. There is no doubt that DCTs and digitalization are starting to transform clinical research, but will they become the norm?

  9. Using RWE In Clinical Trials: Challenges & Opportunities 9/19/2022

    What are real-world data (RWD) and real-world evidence (RWE), and how can we overcome the challenges of integrating them into clinical trials to produce better outcomes?

  10. Walgreens Is Ready To Re-Envision Recruitment, DCTs, And RWE 9/12/2022

    Since becoming CEO of Walgreens Boots Alliance (WBA) in March 2021, Rosalind Brewer has been focused on healthcare and what the company could do to help its patients. WBA refers to the integrated healthcare, pharmacy, and retail store that currently serves millions of customers and patients every day. This past June, the company launched its clinical trial business.